What is the ROE (Return on Equity) of BioCardia this year?
The ROE of BioCardia this year is 7.22 undefined.
BioCardia ROE 2024
BioCardia ROE
7.22
Ticker
BCDA
ISIN
US09060U5074
WKN
A2PLXH
In 2024, BioCardia's return on equity (ROE) was 7.22, a -396.37% increase from the -2.44 ROE in the previous year.
BioCardia Aktienanalyse
What does BioCardia do?
BioCardia Inc is a medical technology company based in San Carlos, California, founded in 1994. They specialize in the development of medical devices used in the treatment of heart diseases. BioCardia has three main product lines: the Helix™ Biotherapy Platform, the Morph™ Transseptal Systems, and the CYPHER Select™ Balloon Catheter. The Helix™ Biotherapy Platform was developed to treat cardiovascular diseases using regenerative medicine. The system utilizes patient's own stem cells to repair damaged heart tissue and reduce the risk of heart attacks. This therapy method can significantly improve the quality of life and survival chances of patients with heart diseases. The Morph™ Transseptal Systems are used for minimally invasive removal of blood clots. They consist of a flexible guide wire and a catheter device that allows the doctor to remove the clot in the heart without performing an open surgery. This procedure is faster, safer, and less invasive than conventional methods. The CYPHER Select™ Balloon Catheter is used to open narrowed arteries in the heart. The balloon is inserted into the artery and inflated to break up the narrowing. Then, a medication is released to prevent the recurrence of the narrowing. This procedure is minimally invasive and enables faster recovery of patients. BioCardia is also involved in clinical research and collaborates closely with renowned institutions such as the Stanford University Medical Center. Through clinical studies, BioCardia collects important data on the efficacy and safety of its products. The results of these studies are published in medical journals and contribute to the advancement of medical practice. BioCardia's business model is based on the development and commercialization of innovative medical devices for the treatment of heart diseases. The company has built a portfolio of products and platforms that allow it to specialize in various areas of cardiovascular medicine. BioCardia also utilizes partnerships and collaborations to market its products and services. Overall, BioCardia is one of the leading companies in the field of medical devices for the treatment of heart diseases. With a portfolio of innovative products and a strong presence in medical research, BioCardia is well positioned to solidify its position as a market leader in the industry. BioCardia ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding BioCardia's Return on Equity (ROE)
BioCardia's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing BioCardia's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
BioCardia's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in BioCardia’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about BioCardia stock
How has the Return on Equity (ROE) of BioCardia developed compared to the previous year?
The ROE of BioCardia has increased by -396.37% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of BioCardia?
A high ROE indicates that BioCardia generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of BioCardia?
A low ROE can indicate that BioCardia is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of BioCardia affect the company?
A change in ROE (Return on Equity) of BioCardia can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of BioCardia?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of BioCardia?
Some factors that can influence BioCardia's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does BioCardia pay?
Over the past 12 months, BioCardia paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BioCardia is expected to pay a dividend of 0 USD.
What is the dividend yield of BioCardia?
The current dividend yield of BioCardia is .
When does BioCardia pay dividends?
BioCardia pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of BioCardia?
BioCardia paid dividends every year for the past 0 years.
What is the dividend of BioCardia?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is BioCardia located?
BioCardia is assigned to the 'Health' sector.
Wann musste ich die Aktien von BioCardia kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of BioCardia from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.
When did BioCardia pay the last dividend?
The last dividend was paid out on 10/2/2024.
What was the dividend of BioCardia in the year 2023?
In the year 2023, BioCardia distributed 0 USD as dividends.
In which currency does BioCardia pay out the dividend?
The dividends of BioCardia are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von BioCardia
Our stock analysis for BioCardia Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioCardia Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
